Medicinal Chemistry Division, Indian Institute of Integrative Medicine, Sanat Nagar, Srinagar, India.
Phytomedicine. 2013 Dec 15;21(1):1-14. doi: 10.1016/j.phymed.2013.07.015. Epub 2013 Sep 12.
Natural product based drugs constitute a substantial proportion of the pharmaceutical market particularly in the therapeutic areas of infectious diseases and oncology. The primary focus of any drug development program so far has been to design selective ligands (drugs) that act on single selective disease targets to obtain highly efficacious and safe drugs with minimal side effects. Although this approach has been successful for many diseases, yet there is a significant decline in the number of new drug candidates being introduced into clinical practice over the past few decades. This serious innovation deficit that the pharmaceutical industries are facing is due primarily to the post-marketing failures of blockbuster drugs. Many analysts believe that the current capital-intensive model-"the one drug to fit all" approach will be unsustainable in future and that a new "less investment, more drugs" model is necessary for further scientific growth. It is now well established that many diseases are multi-factorial in nature and that cellular pathways operate more like webs than highways. There are often multiple ways or alternate routes that may be switched on in response to the inhibition of a specific target. This gives rise to the resistant cells or resistant organisms under the specific pressure of a targeted agent, resulting in drug resistance and clinical failure of the drug. Drugs designed to act against individual molecular targets cannot usually combat multifactorial diseases like cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory diseases. Combination drugs that affect multiple targets simultaneously are better at controlling complex disease systems and are less prone to drug resistance. This multicomponent therapy forms the basis of phytotherapy or phytomedicine where the holistic therapeutic effect arises as a result of complex positive (synergistic) or negative (antagonistic) interactions between different components of a cocktail. In this approach, multicomponent therapy is considered to be advantageous for multifactorial diseases, instead of a "magic bullet" the metaphor of a "herbal shotgun" might better explain the state of affairs. The different interactions between various components might involve the protection of an active substance from decomposition by enzymes, modification of transport across membranes of cells or organelles, evasion of multidrug resistance mechanisms among others.
天然产物药物构成了药物市场的重要组成部分,尤其是在传染病和肿瘤学等治疗领域。迄今为止,任何药物开发计划的主要重点都是设计选择性配体(药物),这些配体作用于单一的选择性疾病靶点,以获得高效、安全且副作用最小的药物。尽管这种方法在许多疾病中都取得了成功,但在过去几十年中,进入临床实践的新药候选物数量却显著下降。制药行业面临的这种严重创新不足主要是由于重磅炸弹药物的上市后失败。许多分析人士认为,当前资本密集型模式——“一种药物适合所有人”的方法在未来将不可持续,需要一种新的“投资少、药物多”的模式来推动进一步的科学发展。现在已经确定,许多疾病本质上是多因素的,细胞途径更像是网络而不是高速公路。通常有多种方法或替代途径可以在特定靶点被抑制时被激活。这导致在特定靶向药物的特定压力下产生耐药细胞或耐药生物,从而导致药物耐药性和药物临床失败。针对单个分子靶点设计的药物通常无法治疗癌症等多因素疾病,也无法治疗影响多种组织或细胞类型的疾病,如糖尿病和免疫炎症性疾病。同时作用于多个靶点的联合药物更能控制复杂的疾病系统,且不易产生耐药性。这种多组分治疗构成了植物疗法或植物药的基础,整体治疗效果是由于鸡尾酒中不同成分之间复杂的积极(协同)或消极(拮抗)相互作用产生的。在这种方法中,多组分治疗被认为对多因素疾病是有利的,而不是“万能药”,“草药霰弹枪”的比喻可能更能解释这种情况。不同成分之间的不同相互作用可能涉及保护活性物质免受酶的分解、改变细胞或细胞器的跨膜运输、逃避多药耐药机制等。